drugset / Trial / NCT03139981
A Study To Evaluate ASN002 In Subjects With Atopic Dermatitis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a dose escalation study to test the safety, tolerability and preliminary efficacy of ASN002 in people with moderate to severe atopic dermatitis (AD).
Timeline
- Start
- 2017-04-12
- Primary completion
- 2017-11-05
- Completion
- 2017-12-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gusacitinib | Small molecule | 20 mg | — |
| Subject | Gusacitinib | Small molecule | 40 mg | — |
| Subject | Gusacitinib | Small molecule | 80 mg | — |
| Subject | Gusacitinib | Small molecule | 120 mg | — |